Modifying the glycosylation profile of SARS-CoV-2 spike-based subunit vaccines alters focusing of the humoral immune response in a mouse model.

Saved in:
Bibliographic Details
Title: Modifying the glycosylation profile of SARS-CoV-2 spike-based subunit vaccines alters focusing of the humoral immune response in a mouse model.
Authors: Renner TM; National Research Council Canada, Human Health Therapeutics Research Centre, Ottawa, Ontario, Canada., Stuible M; National Research Council Canada, Human Health Therapeutics Research Centre, Montreal, Quebec, Canada., Rossotti MA; National Research Council Canada, Human Health Therapeutics Research Centre, Ottawa, Ontario, Canada., Rohani N; National Research Council Canada, Human Health Therapeutics Research Centre, Montreal, Quebec, Canada., Cepero-Donates Y; National Research Council Canada, Human Health Therapeutics Research Centre, Montreal, Quebec, Canada., Sauvageau J; National Research Council Canada, Human Health Therapeutics Research Centre, Ottawa, Ontario, Canada., Deschatelets L; National Research Council Canada, Human Health Therapeutics Research Centre, Ottawa, Ontario, Canada., Dudani R; National Research Council Canada, Human Health Therapeutics Research Centre, Ottawa, Ontario, Canada., Harrison BA; National Research Council Canada, Human Health Therapeutics Research Centre, Ottawa, Ontario, Canada., Baardsnes J; National Research Council Canada, Human Health Therapeutics Research Centre, Montreal, Quebec, Canada., Koyuturk I; National Research Council Canada, Human Health Therapeutics Research Centre, Montreal, Quebec, Canada.; Department of Biochemistry and Molecular Medicine, University of Montreal, Montreal, Quebec, Canada., St Michael F; National Research Council Canada, Human Health Therapeutics Research Centre, Ottawa, Ontario, Canada., Hill JJ; National Research Council Canada, Human Health Therapeutics Research Centre, Ottawa, Ontario, Canada., Hemraz UD; National Research Council Canada, Human Health Therapeutics Research Centre, Montreal, Quebec, Canada., Lenferink AEG; National Research Council Canada, Human Health Therapeutics Research Centre, Montreal, Quebec, Canada., Tanha J; National Research Council Canada, Human Health Therapeutics Research Centre, Ottawa, Ontario, Canada.; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada., Fernandes B; iBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal., Roldao A; iBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal., McCluskie MJ; National Research Council Canada, Human Health Therapeutics Research Centre, Ottawa, Ontario, Canada., Akache B; National Research Council Canada, Human Health Therapeutics Research Centre, Ottawa, Ontario, Canada., Durocher Y; National Research Council Canada, Human Health Therapeutics Research Centre, Montreal, Quebec, Canada. Yves.Durocher@nrc-cnrc.gc.ca.; Department of Biochemistry and Molecular Medicine, University of Montreal, Montreal, Quebec, Canada. Yves.Durocher@nrc-cnrc.gc.ca.
Source: Communications medicine [Commun Med (Lond)] 2025 Apr 11; Vol. 5 (1), pp. 111. Date of Electronic Publication: 2025 Apr 11.
Publication Type: Journal Article
Journal Info: Publisher: Nature Portfolio Country of Publication: England NLM ID: 9918250414506676 Publication Model: Electronic Cited Medium: Internet ISSN: 2730-664X (Electronic) Linking ISSN: 2730664X NLM ISO Abbreviation: Commun Med (Lond) Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2730-664X
DOI:10.1038/s43856-025-00830-w